ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP94-20 Commercial Pharmacy Benefit Exclusion for Condylox®, Lyumjev™, Veregen® and Zilxi™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 14, 2020
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2381 - 2390 လၢ 3685 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP103-20 Commercial Pharmacy Benefit Exclusion for Emtricitabine-Tenofovir Disoproxil Fumarate Tablet 200-300 mg
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 28, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP104-20 Update: Cotiviti to Perform Focused and Limited Hospital Bill Validation (HBV) Services
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 28, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP99-20 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Insulin Pump PA with QL
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 14, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P79-20 Change in Medical Necessity Criteria to InterQual® for Substance Use Disorder Admissions
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 02, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P83-20 eviCore Healthcare Specialty Utilization Management (UM) Program - Laboratory Management Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 02, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P77-20 2021 Medicare Product Acupuncture Benefit Changes
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 02, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P76-20 2021 Renewal Changes Summary for Institutional Providers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 01, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2020 October Bulletins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 01, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P15R1-20 Update: Change in Requirements for Newborn Precertification Process for Minnesota Health Care Programs
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 01, 2020